Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer.

Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer.

This study aimed to assess the efficacy and safety of combination treatment with lenalidomide and cetuximab in KRAS-mutant metastatic colorectal cancer patients. This was a phase II multicenter, open-label trial comprising a safety lead-in phase (phase IIa) to determine the maximum tolerated dose, a...

Full description

Bibliographic Details
Main Authors: Salvatore Siena, Eric Van Cutsem, Mingyu Li, Ulf Jungnelius, Alfredo Romano, Robert Beck, Katia Bencardino, Maria Elena Elez, Hans Prenen, Mireia Sanchis, Andrea Sartore-Bianchi, Sabine Tejpar, Anita Gandhi, Tao Shi, Josep Tabernero
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3823943?pdf=render

Internet

http://europepmc.org/articles/PMC3823943?pdf=render

Similar Items